Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation

Joseph L. Blackshear; Miguel Zabalgoitia; Gregory Pennock; Paul Fenster; Richard Strauss; Jonathan Halperin; Richard Asinger; Lesly A. Pearce

doi:10.1016/S0002-9149(98)00886-8

Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation

Joseph L. Blackshear, Miguel Zabalgoitia, Gregory Pennock, Paul Fenster, Richard Strauss, Jonathan Halperin, Richard Asinger, Lesly A. Pearce

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Patients with atrial fibrillation and with documented oartic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0) had an annual rate of cholesterol embolization of 0.7% (95% confidence interval [CI] 0.1% to 5.3%/patient-year). Warfarin-assigned patients with plaque had a lower rate of embolic events (5.9%/year; 95% CI 3.0 to 12) than those on combination low-dose warfarin (international normalized ratio <1.5) plus aspirin (17.3%/year; 95% CI 11 to 27; p = 0.01).

Original language	English (US)
Pages (from-to)	453-455
Number of pages	3
Journal	American Journal of Cardiology
Volume	83
Issue number	3
DOIs	https://doi.org/10.1016/S0002-9149(98)00886-8
State	Published - Feb 1 1999
Externally published	Yes

Bibliographical note

Funding Information:
This study was supported by Grants R01-NS-33551 and R01-NS-24224 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.

Access

10.1016/S0002-9149(98)00886-8

OpenUrl availability

Full text

Cite this

@article{64e3662ff5e6444ca7ddecb348acef3f,

title = "Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation",

abstract = "Patients with atrial fibrillation and with documented oartic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0) had an annual rate of cholesterol embolization of 0.7% (95% confidence interval [CI] 0.1% to 5.3%/patient-year). Warfarin-assigned patients with plaque had a lower rate of embolic events (5.9%/year; 95% CI 3.0 to 12) than those on combination low-dose warfarin (international normalized ratio <1.5) plus aspirin (17.3%/year; 95% CI 11 to 27; p = 0.01).",

author = "Blackshear, {Joseph L.} and Miguel Zabalgoitia and Gregory Pennock and Paul Fenster and Richard Strauss and Jonathan Halperin and Richard Asinger and Pearce, {Lesly A.}",

note = "Funding Information: This study was supported by Grants R01-NS-33551 and R01-NS-24224 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland. ",

year = "1999",

month = feb,

day = "1",

doi = "10.1016/S0002-9149(98)00886-8",

language = "English (US)",

volume = "83",

pages = "453--455",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation

AU - Blackshear, Joseph L.

AU - Zabalgoitia, Miguel

AU - Pennock, Gregory

AU - Fenster, Paul

AU - Strauss, Richard

AU - Halperin, Jonathan

AU - Asinger, Richard

AU - Pearce, Lesly A.

N1 - Funding Information: This study was supported by Grants R01-NS-33551 and R01-NS-24224 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - Patients with atrial fibrillation and with documented oartic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0) had an annual rate of cholesterol embolization of 0.7% (95% confidence interval [CI] 0.1% to 5.3%/patient-year). Warfarin-assigned patients with plaque had a lower rate of embolic events (5.9%/year; 95% CI 3.0 to 12) than those on combination low-dose warfarin (international normalized ratio <1.5) plus aspirin (17.3%/year; 95% CI 11 to 27; p = 0.01).

AB - Patients with atrial fibrillation and with documented oartic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0) had an annual rate of cholesterol embolization of 0.7% (95% confidence interval [CI] 0.1% to 5.3%/patient-year). Warfarin-assigned patients with plaque had a lower rate of embolic events (5.9%/year; 95% CI 3.0 to 12) than those on combination low-dose warfarin (international normalized ratio <1.5) plus aspirin (17.3%/year; 95% CI 11 to 27; p = 0.01).

UR - http://www.scopus.com/inward/record.url?scp=0033080904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033080904&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(98)00886-8

DO - 10.1016/S0002-9149(98)00886-8

M3 - Article

C2 - 10072242

AN - SCOPUS:0033080904

SN - 0002-9149

VL - 83

SP - 453

EP - 455

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 3

ER -

Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this